ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2428

Differences in Dyspigmentation and Scarring Across Cutaneous Lupus Erythematosus Categories and Subtypes

Shae Chambers1, Aretha On2, Xiwei Yang2, Lais Lopes Almeida Gomes1, Touraj Khosravi-Hafshejani3, Hammad Ali3, Rui Feng4 and Victoria Werth1, 1University of Pennsylvania, Philadelphia, PA, 2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 3Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, U.S./Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, U.S., Philadelphia, PA, 4Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, Autoinflammatory diseases, Dermatology, lupus-like disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Cutaneous lupus erythematosus (CLE) is a chronic autoimmune disease marked by skin lesions that can vary in appearance and severity. Subacute cutaneous erythematosus (SCLE), acute cutaneous erythematosus (ACLE), and chronic cutaneous erythematosus (CCLE) make up the CLE categories and CCLE may be further subtyped. While dyspigmentation and scarring are recognized as complications of discoid lupus erythematosus (DLE), no studies have investigated scarring and dyspigmentation across all the CLE categories and subtypes.

Methods: To better characterize dyspigmentation and scarring in CLE, we conducted a cross-sectional review of our IRB-approved CLE database at the University of Pennsylvania. Patients were divided by category and CCLE subtype. Dyspigmentation and scarring were quantified using components of the CLE Disease Area and Severity Index damage (CLASI-D) score. Data on dyspigmentation and scarring were captured from the patient visit where dyspigmentation was highest. The Kruskal-Wallis test was used to compare dyspigmentation and scarring scores across CLE categories and CCLE subtypes. A Post-hoc Dunn analysis was used to check for pairwise comparisons between groups. The Spearman’s rank-order correlation test was used to assess the correlations between dyspigmentation and scarring.

Results: A total of 500 patients were included in the study. Dyspigmentation and scarring significantly differed between CLE categories and CCLE subtypes (p< .01). Across categories, CCLE had the highest medians for dyspigmentation and scarring. Across CCLE subtypes, DLE had the highest medians for dyspigmentation and scarring. Dyspigmentation and scarring were significantly positively correlated in CCLE, DLE, and LE Panniculitis (p< .01).

Conclusion: Our findings show that scarring and dyspigmentation do not necessarily correlate in CLE except for CCLE as a whole and the CCLE subtypes of DLE and LE panniculitis. These CLE categories and CCLE subtypes are known to have higher rates of long-lasting disease damage. Dyspigmentation and scarring correlation differences highlight the importance of accurate assessment and documentation of both elements of damage. Our results reflect important differences in the CLE categories and CCLE subtypes which may be helpful for clinicians and patients as they navigate the course of the disease.

Supporting image 1Key: CLE = cutaneous lupus erythematous, ACLE = acute cutaneous lupus erythematous, SCLE = subacute cutaneous lupus erythematous, CCLE = chronic cutaneous lupus erythematous, DLE = discoid lupus erythematous, LET = tumid lupus erythematous, Q1 = first quartile, Q3 = third quartile. Values for median dyspigmentation and median scarring correlate to Cutaneous Lupus Erythematous Disease Area and Severity Index damage score dyspigmentation and scarring aspects respectively. P-values in columns in columns three and five represent differences in dyspigmentation and scarring across CLE categories and CCLE subtypes using the Kruskal-Wallis test. R-values represent correlations between dyspigmentation and scarring across CLE categories and CCLE subtypes using the Spearman’s rank-order correlation test.

Supporting image 2Figure 1. Comparison of median dyspigmentation and scarring scores across Cutaneous Lupus Erythematosus Categories. Dunn-Bonferroni post-hoc test run to analyze pairwise comparisons following Kruskal-Wallis test. CLE = cutaneous lupus erythematosus, ACLE = acute cutaneous lupus erythematous, SCLE = subacute cutaneous lupus erythematous, CCLE = chronic cutaneous lupus erythematous.

Supporting image 3Figure 2. Correlation of scarring and dyspigmentation in Cutaneous Lupus Erythematosus Categories & Subtypes. Spearman’s rank-order correlation between scarring and dyspigmentation scores for each patient visit where dyspigmentation was highest. (A) CCLE (B) DLE (C) Panniculitis. r = Spearman’s rank correlation coefficient, CCLE = chronic cutaneous lupus erythematous, DLE = discoid lupus erythematous.


Disclosures: S. Chambers: None; A. On: None; X. Yang: None; L. Lopes Almeida Gomes: None; T. Khosravi-Hafshejani: Pfizer, 1; H. Ali: None; R. Feng: None; V. Werth: AbbVie/Abbott, 2, Alpine Immune Sciences, 2, Amgen, 2, 5, AnaptysBio, 2, argenx, 2, AstraZeneca, 2, 5, Biogen, 2, 5, Bristol-Myers Squibb(BMS), 2, 5, Cabaletta Bio, 2, Calyx, 2, Caribou, 2, CESAS Medical, 6, Corbus Pharmaceuticals, 5, Crisalis, 2, CSL Behring, 2, 5, Cugene, 2, Eli Lilly, 2, EMD Serono, 2, Evommune, 2, Gilead, 2, 5, GlaxoSmithKlein(GSK), 2, Horizon, 2, 5, Immunovant, 2, Innovaderm, 2, Janssen, 2, Kyowa Kirin, 2, MAPI Trust, 9, Merck KGaA, Darmstadt, Germany, 2, N/A, 12, The University of Pennsylvania owns the copyright for the CLASI., Nektar, 2, Nuvig Pharmaceuticals, 2, Pfizer, 2, 5, Priovant, 5, Regeneron, 2, 5, Rome Therapeutics, 2, 5, Sanofi, 2, Takeda, 2, UCB, 2, Ventus, 2, 5, Viela Bio, 2, 5, Xencor, 2.

To cite this abstract in AMA style:

Chambers S, On A, Yang X, Lopes Almeida Gomes L, Khosravi-Hafshejani T, Ali H, Feng R, Werth V. Differences in Dyspigmentation and Scarring Across Cutaneous Lupus Erythematosus Categories and Subtypes [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/differences-in-dyspigmentation-and-scarring-across-cutaneous-lupus-erythematosus-categories-and-subtypes/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differences-in-dyspigmentation-and-scarring-across-cutaneous-lupus-erythematosus-categories-and-subtypes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology